Atalanta Sosnoff Capital Trimmed Eastman Chem Co (EMN) Position By $413,700; 10 Analysts Are Bullish Insmed (INSM) Last Week

Eastman Chemical Company (NYSE:EMN) Logo

Among 12 analysts covering Insmed (NASDAQ:INSM), 10 have Buy rating, 0 Sell and 2 Hold. Therefore 83% are positive. Insmed had 29 analyst reports since August 10, 2015 according to SRatingsIntel. Stifel Nicolaus maintained the stock with “Buy” rating in Thursday, August 3 report. The firm has “Buy” rating by Cowen & Co given on Thursday, July 20. The rating was upgraded by Zacks on Thursday, August 20 to “Hold”. Cowen & Co maintained the shares of INSM in report on Monday, September 11 with “Buy” rating. The rating was downgraded by UBS on Monday, November 9 to “Neutral”. The firm has “Neutral” rating by Citigroup given on Wednesday, March 16. The rating was initiated by Robert W. Baird on Monday, July 10 with “Buy”. As per Wednesday, March 14, the company rating was maintained by Leerink Swann. H.C. Wainwright maintained it with “Buy” rating and $35.0 target in Wednesday, September 6 report. H.C. Wainwright maintained Insmed Incorporated (NASDAQ:INSM) rating on Thursday, January 4. H.C. Wainwright has “Buy” rating and $35.0 target. See Insmed Incorporated (NASDAQ:INSM) latest ratings:

07/06/2018 Broker: H.C. Wainwright Rating: Buy New Target: $35.0000 Maintain
23/04/2018 Broker: Credit Suisse Old Rating: Neutral New Rating: Outperform Old Target: $31 Upgrade
21/03/2018 Broker: Morgan Stanley Rating: Overweight New Target: $39 Initiates Coverage On
14/03/2018 Broker: Leerink Swann Rating: Buy New Target: $39.0 Maintain
04/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $43.0 Upgrade
04/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $42.0 Maintain
04/01/2018 Broker: H.C. Wainwright Rating: Buy New Target: $35.0 Maintain

Atalanta Sosnoff Capital Llc decreased Eastman Chem Co (EMN) stake by 1.23% reported in 2018Q1 SEC filing. Atalanta Sosnoff Capital Llc sold 3,940 shares as Eastman Chem Co (EMN)’s stock rose 1.97%. The Atalanta Sosnoff Capital Llc holds 315,717 shares with $33.33M value, down from 319,657 last quarter. Eastman Chem Co now has $15.63B valuation. The stock increased 0.06% or $0.07 during the last trading session, reaching $109.47. About 802,429 shares traded. Eastman Chemical Company (NYSE:EMN) has risen 33.38% since June 13, 2017 and is uptrending. It has outperformed by 20.81% the S&P500. Some Historical EMN News: ; 26/04/2018 – EASTMAN CHEMICAL CO – QTRLY SHR $2.00; 26/04/2018 – Eastman Chem 1Q Adj EPS $2.23; 30/05/2018 – Eastman Chemical Presenting at Deutsche Bank Conference Jun 6; 27/04/2018 – EASTMAN EARNINGS CALL CONCLUDES; 16/05/2018 – Republicans hope Eastman sits too far to the ideological left to beat incumbent GOP Rep. Don Bacon in the swing district; 27/04/2018 – EASTMAN STILL SEES EPS GROWTH OF 8%-12% LONG TERM; 29/05/2018 – Eastman Chemical Closes Below 50-Day Moving Average: Technicals; 09/05/2018 – EASTMAN CHEMICAL – ADDITIONAL PLANNED EXPANSION OF COPOLYESTER PRODUCTION TO BE ADDED AT KINGSPORT SITE; 07/05/2018 – Eastman Chemical at Wells Fargo Industrials Conference Tomorrow; 26/04/2018 – Eastman touts 10th anniversary of Eastman Tritan™ copolyester at NPE

Among 17 analysts covering Eastman Chemical Company (NYSE:EMN), 9 have Buy rating, 2 Sell and 6 Hold. Therefore 53% are positive. Eastman Chemical Company has $125.0 highest and $73 lowest target. $107.50’s average target is -1.80% below currents $109.47 stock price. Eastman Chemical Company had 61 analyst reports since July 30, 2015 according to SRatingsIntel. RBC Capital Markets maintained the shares of EMN in report on Sunday, July 30 with “Hold” rating. RBC Capital Markets maintained Eastman Chemical Company (NYSE:EMN) on Tuesday, September 5 with “Hold” rating. The stock has “Buy” rating by Cowen & Co on Thursday, July 13. Deutsche Bank maintained the shares of EMN in report on Thursday, September 3 with “” rating. Jefferies maintained Eastman Chemical Company (NYSE:EMN) rating on Friday, June 16. Jefferies has “Buy” rating and $90 target. On Tuesday, October 10 the stock rating was downgraded by Nomura to “Neutral”. The firm has “Sector Perform” rating by RBC Capital Markets given on Monday, October 31. As per Wednesday, October 14, the company rating was initiated by RBC Capital Markets. The firm has “Hold” rating given on Friday, February 2 by SunTrust. The stock of Eastman Chemical Company (NYSE:EMN) has “Neutral” rating given on Wednesday, September 7 by Citigroup.

Since February 7, 2018, it had 0 insider buys, and 11 sales for $12.84 million activity. Another trade for 24,834 shares valued at $2.62M was made by LICH BRAD A on Tuesday, May 8. On Thursday, March 1 King Scott V. sold $996,437 worth of Eastman Chemical Company (NYSE:EMN) or 9,883 shares. RAISBECK DAVID W sold $406,360 worth of stock or 4,000 shares. The insider Golden David A. sold 8,600 shares worth $906,268. On Friday, February 9 the insider BOLDEA LUCIAN sold $315,875. 2,710 shares valued at $277,016 were sold by WARMACK DAMON CARY on Friday, February 23. 4,000 shares were sold by DEMERITT STEPHEN R, worth $399,360.

Investors sentiment decreased to 0.92 in Q1 2018. Its down 0.25, from 1.17 in 2017Q4. It fall, as 45 investors sold EMN shares while 212 reduced holdings. 71 funds opened positions while 166 raised stakes. 115.78 million shares or 0.82% less from 116.74 million shares in 2017Q4 were reported. Boston Advsr Lc accumulated 0.03% or 9,317 shares. Alliancebernstein Lp invested in 287,532 shares. Apg Asset Nv holds 1.39M shares or 0.23% of its portfolio. Moreover, Mark Sheptoff Financial Planning Ltd Liability Corp has 0.34% invested in Eastman Chemical Company (NYSE:EMN) for 4,650 shares. Mason Street Advsrs Ltd Liability Com invested 0.05% in Eastman Chemical Company (NYSE:EMN). Magnetar Fin Llc reported 3,536 shares or 0.01% of all its holdings. Kornitzer Cap Management Ks holds 110,095 shares or 0.2% of its portfolio. Lazard Asset Mgmt Limited Liability Company, New York-based fund reported 349,069 shares. Brinker owns 14,834 shares or 0.06% of their US portfolio. Fmr invested in 0.03% or 2.33 million shares. Lord Abbett And Ltd Liability Corp accumulated 295,856 shares or 0.09% of the stock. Franklin Resources invested 0.02% of its portfolio in Eastman Chemical Company (NYSE:EMN). Zeke Capital Advsr Ltd Liability Co reported 0.03% in Eastman Chemical Company (NYSE:EMN). Walter & Keenan Consulting Co Mi Adv invested in 0.18% or 3,900 shares. D E Shaw And Incorporated has 183,803 shares for 0.03% of their portfolio.

Analysts await Eastman Chemical Company (NYSE:EMN) to report earnings on July, 26. They expect $2.21 EPS, up 11.62% or $0.23 from last year’s $1.98 per share. EMN’s profit will be $315.50M for 12.38 P/E if the $2.21 EPS becomes a reality. After $2.23 actual EPS reported by Eastman Chemical Company for the previous quarter, Wall Street now forecasts -0.90% negative EPS growth.

Another recent and important Eastman Chemical Company (NYSE:EMN) news was published by Seekingalpha.com which published an article titled: “Tracking Alex Roepers’ Atlantic Investment Management Portfolio – Q1 2018 Update” on May 24, 2018.

Atalanta Sosnoff Capital Llc increased Alphabet Inc Class A stake by 7,086 shares to 107,561 valued at $111.56M in 2018Q1. It also upped Bank Of America Corporation (NYSE:BAC) stake by 173,437 shares and now owns 4.47M shares. Dollar General Corp (NYSE:DG) was raised too.

Since May 29, 2018, it had 0 buys, and 1 sale for $1.05 million activity. Schaeffer Orlov S Nicole had sold 37,575 shares worth $1.05M.

More notable recent Insmed Incorporated (NASDAQ:INSM) news were published by: Seekingalpha.com which released: “Insmed: PDUFA Date Will Be A Game Changer” on June 04, 2018, also Globenewswire.com with their article: “Insmed to Present at Three June Conferences” published on June 07, 2018, Globenewswire.com published: “Insmed Appoints Leo Lee to its Board of Directors” on May 17, 2018. More interesting news about Insmed Incorporated (NASDAQ:INSM) were released by: Streetinsider.com and their article: “Insmed (INSM) Announces FDA Acceptance for Filing of NDA for ALIS in NTM Lung Disease Caused by MAC” published on May 16, 2018 as well as Nasdaq.com‘s news article titled: “Insmed Announces Presentations at the American Thoracic Society 2018 International Conference” with publication date: May 22, 2018.

The stock increased 1.37% or $0.39 during the last trading session, reaching $28.8. About 232,922 shares traded. Insmed Incorporated (NASDAQ:INSM) has risen 61.09% since June 13, 2017 and is uptrending. It has outperformed by 48.52% the S&P500. Some Historical INSM News: ; 16/05/2018 – INSMED REPORTS FDA ACCEPTANCE FOR FILING OF NDA FOR ALIS IN NTM; 02/05/2018 – Insmed: Actively Preparing for Potential Pdt Launch of ALIS in 4Q 2018; 22/05/2018 – lnsmed Announces Presentations at the American Thoracic Society 2018 International Conference; 29/03/2018 – INSMED – ANTICIPATES RECEIVING A SIX-MONTH PRIORITY REVIEW AND THAT NDA WILL BE REVIEWED BY DIVISION OF ANTI-INFECTIVE PRODUCTS; 02/05/2018 – Insmed 1Q Loss $68.5M; 17/05/2018 – INSMED APPOINTS LEO LEE TO ITS BOARD OF DIRECTORS; 14/03/2018 Biopharmaceutical Veteran Joins CURE Pharmaceutical to Lead Manufacturing; 16/05/2018 – INSMED: PDUFA ACTION DATE FOR ALIS SET FOR SEPT. 28; 02/05/2018 – INSMED SAYS SUBMITTED NDA TO FDA FOR ALIS IN NTM LUNG DISEASE; 02/05/2018 – Insmed 1Q-End Cash and Cash Equivalents $686.6M

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company has market cap of $2.21 billion. The companyÂ’s lead product candidate is ARIKAYCE or liposomal amikacin for inhalation, a formulation of amikacin that is in late-stage clinical development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by Mycobacterium avium complex. It currently has negative earnings. It is also developing INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1, which has completed a Phase I clinical study for activating neutrophil serine proteases that are implicated in the pathology of chronic inflammatory lung diseases, such as non-cystic fibrosis bronchiectasis; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug, which has completed a Phase I clinical study for treating rare pulmonary disorders, including pulmonary arterial hypertension.

Eastman Chemical Company (NYSE:EMN) Institutional Positions Chart